2 results match your criteria: "Hospitalier Paris Sain-Joseph[Affiliation]"
Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey.
HPB (Oxford)
November 2023
Department of Upper Gastrointestinal Surgery, St Vincent's Hospital Melbourne, Melbourne, Australia; Department of Surgery, Monash University, Melbourne, Victoria, Australia; Monash Health, Melbourne, Victoria, Australia. Electronic address:
Article Synopsis
- Pancreatic ductal adenocarcinoma (PDAC) is a serious cancer where accurately assessing resectability through CT scans is essential for determining the best treatment options for patients.
- In a study involving 96 clinicians, it was found that there was significant variability in how different surgeons and radiologists agreed on the resectability of pancreatic tumors based on CT scans.
- The results highlighted a fair overall agreement score of 0.32, with radiologists demonstrating better consistency than surgeons, indicating a need for more standardized assessment processes and central reviews in future treatments and studies.
Epidemiological Study to Assess the Prevalence of Lung Cancer in patients with smoking-associated atherosclerotic cardiovascular diseases: PREVALUNG study protocol.
BMJ Open
December 2022
Hôpital Marie Lannelongue Groupe, Hospitalier Paris Sain-Joseph, Le Plessis-Robinson, France.
Introduction: Eligibility criteria definition for a lung cancer screening (LCS) is an unmet need. We hypothesised that patients with a history of atheromatous cardiovascular disease (ACVD) associated with tobacco consumption are at risk of lung cancer (LC). The main objective is to assess LC prevalence among patients with ACVD and history of tobacco consumption by using low-dose chest CT scan.
View Article and Find Full Text PDF